Celecoxib
| Subclass of | chemical compound  |
|---|---|
| Get use | Medication |
| Stylized name | CeleBREX |
| Chemical formula | C₁₇H₁₄F₃N₃O₂S |
| Canonical SMILES | CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F |
| Active ingredient in | Onsenal, Celebrex |
| World Health Organisation international non-proprietary name | celecoxib |
| Physically dey interact plus | Carbonic anhydrase 12, Prostaglandin-endoperoxide synthase 2 |
| Legal status (medicine) | boxed warning |
| Pregnancy category | Australian pregnancy category B3, US pregnancy category C |
| LiverTox likelihood score | LiverTox toxicity likelihood category B |
| Subject has role | cyclooxygenase inhibitors, COX-2 inhibitor, non-steroidal anti-inflammatory drug |
Celecoxib, dem sell under de brand name Celebrex among odas, be a COX-2 inhibitor den nonsteroidal anti-inflammatory drug (NSAID).[1] E be used to treat de pain den inflammation insyd osteoarthritis, acute pain insyd adults, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, painful menstruation, den juvenile rheumatoid arthritis.[1] E sanso fi be used to decrease de risk of colorectal adenomas insyd people plus familial adenomatous polyposis.[1] Dem dey take am by mouth.[1] Benefits typically be seen within an hour.[1]
Common side effects dey include abdominal pain, nausea, den diarrhea.[1] Serious side effects fi include heart attacks, strokes, gastrointestinal perforation, gastrointestinal bleeding, kidney failure, den anaphylaxis.[1][2] Ein use no be recommended insyd people at high risk for heart disease.[3][4] De risks be similar to oda NSAIDs, such as ibuprofen den naproxen.[5] Ein use insyd de later part of pregnancy anaa during breastfeeding no be recommended.[1]
Celecoxib demonstrate adjunctive benefits insyd major depression den efficacy in reducing polyp recurrence insyd familial adenomatous polyposis, while dem sanso dey investigate am for broader psychiatric, anticancer, den chemopreventive applications.
Dem patent celecoxib insyd 1993 wey e cam into medical use insyd 1999.[6] E be available as a generic medication.[7] Insyd 2023, e be de 111th most commonly prescribed medication insyd de United States, plus more dan 6 million prescriptions.[8][9]
References
[edit | edit source]- 1 2 3 4 5 6 7 8 "Celecoxib Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. 11 November 2019. Archived from the original on 20 May 2019. Retrieved 5 May 2020.
- ↑ Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C (August 2013). "Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials". Lancet. 382 (9894): 769–79. doi:10.1016/S0140-6736(13)60900-9. PMC 3778977. PMID 23726390.
- ↑ Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA (March 2007). "Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association". Circulation. 115 (12): 1634–42. doi:10.1161/circulationaha.106.181424. PMID 17325246.
- ↑ "Should you still take Celebrex?". Consumer Reports. August 2009. Archived from the original on 18 December 2015. Retrieved 27 December 2015.
- ↑ Stein R (25 April 2018). "FDA Panel Affirms Safety Of Painkiller Celebrex". NPR. Archived from the original on 20 May 2018. Retrieved 19 May 2018.
- ↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 522. ISBN 978-3-527-60749-5. Archived from the original on 27 April 2021. Retrieved 13 October 2020.
- ↑ British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 1097–1098. ISBN 978-0-85711-338-2.
- ↑ "Top 300 of 2023". ClinCalc. Archived from the original on 12 August 2025. Retrieved 12 August 2025.
- ↑ "Celecoxib Drug Usage Statistics, United States, 2013 - 2023". ClinCalc. Retrieved 18 August 2025.
Read further
[edit | edit source]- Dean L (2016). "Celecoxib Therapy and CYP2C9 Genotype". In Pratt VM, McLeod HL, Rubinstein WS, et al. (eds.). Medical Genetics Summaries. National Center for Biotechnology Information (NCBI). PMID 28520369. Bookshelf ID: NBK379478.
- Zhang J, Ding EL, Song Y (October 2006). "Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials". JAMA. 296 (13): 1619–32. doi:10.1001/jama.296.13.jrv60015. PMID 16968832.
External links
[edit | edit source]
- "COX-2 Selective (includes Bextra, Celebrex, and Vioxx) and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)". U.S. Food and Drug Administration (FDA). 15 July 2005. Archived from the original on 28 September 2019.
- "FDA Approves Labeling Supplement for Celebrex (celecoxib)". U.S. Food and Drug Administration (FDA). 28 June 2018.
